| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |